anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multiple hardware and software external signaling safeguards are employed by an infusion pump to ensure proper operation and to prevent the possibility of overinfusion or underinfusion due to unauthorized signals. Wireless communications with the infusion pump pass through a communications module, and a collection of interconnected controller cores process communications within the infusion pump. The communication module provides wireless communication and manages all wireless communications with the controller cores. Communication through a wired communication interface is also available but may only be permitted when the infusion pump is not actively infusing. When the infusion pump is actively infusing, no communication via the wired communication interface is permitted. The validity of certificates from external wired and wireless signal sources are checked to ensure the source is authorized to communicate with the infusion pump. In addition, all communications are expected to utilize proprietary messaging protocols. Messages received by the infusion pump in other formats are rejected.
BACKGROUND AND AIMS: The yield of various endoscopic biopsy sampling methods for detection of precursor lesions of noncardia gastric cancer in a real-world setting remains unclear. Our objective was to evaluate the association of endoscopic biopsy sampling methods with detection of gastric intestinal metaplasia (GIM) and gastric dysplasia (GD).
METHODS: We conducted a case-control study of adult patients who underwent EGD with biopsy sampling between 2010 and 2021 in a racially and ethnically diverse U.S. healthcare system. Cases were patients with histopathologic findings of GIM and/or GD. Control subjects were matched 1:1 by age, procedure date, and medical center. We compared the detection of GIM and GD using 4 different biopsy sampling methods: unspecified, specified stomach location, 2+2, and the Sydney protocol. Additionally, we assessed trends in use of sampling methods (Cochrane-Armitage) and identified patient and endoscopist factors associated with their use (logistic regression).
RESULTS: We identified 20,938 GIM and 455 GD matched pairs. A greater proportion of GIM cases were detected using 2+2 (31.3% vs 25.3%, P < .0001) and the Sydney protocol (9.1% vs 1.0%, P < .0001) compared with control subjects. Similarly, a greater proportion of GD cases were detected using the Sydney protocol (15.6% vs .4%, P < .0001). We observed an increasing trend in the use of the Sydney protocol during the study period (3.8%-16.1% in cases, P < .0001; 1%-1.1% in control subjects, P = .005). Male and Asian American patients were more likely to undergo 2+2 or the Sydney protocol, whereas female and Hispanic endoscopists were more likely to perform sampling using these protocols.
CONCLUSIONS: The application of the Sydney protocol is associated with an increased detection of precursor lesions of gastric cancer in routine clinical practice.
Increased gastrointestinal (GI) permeability is associated to several GI conditions that affect millions of people worldwide. Healthy intestinal walls limit only specific molecules to cross into the body. "Leaky gut" is a condition of unregulated and increased gut permeability that allows unwanted antigens, pathogens and microbial toxins into the bloodstream(1). This in turn leads to a subsequent immune response that includes the production of inflammatory mediators. Leaky gut is a key feature in celiac disease, Crohn's disease, inflammatory bowel disease (IBD), and environmental enteropathy and have been associated with systemic diseases including type 1 diabetes, autoimmune hepatitis, and systemic lupus erythematosus (SLE).

The current gold standard for measuring intestinal permeability is the sugar ratio test. Non-metabolized sugars of different molecular sizes are orally administered and the amount of sugar molecules absorbable across the gut lining is then quantified by measuring their relative concentrations in urine. In healthy subjects, low to none of the large-molecule disaccharides can be taken into the circulatory system, while the small-molecule monosaccharides can readily diffuse into the bloodstream. This results in low disaccharide/monosaccharide (DM) ratios for healthy subjects. Subjects with the leaky gut conditions exhibit high DM ratios in their urine. However, the sugar ratio test has low specificity, does not provide specific information on etiology, is challenging to implement when pristine urine samples cannot be collected (e.g. infants), and does not account for spatially heterogeneous disease.

An alternative approach for measuring mucosal permeability is through measuring the voltage across the intestinal wall (Intestinal potential difference; IPD) that changes with intestinal permeability. The Tearney lab has developed an IPD measuring device (IPD probe) that can be deployed trans-nasally and can measure the intestinal potential difference in real time at selected locations of the gut. The probe contains a central channel that allows us to infuse specific ionic solutions into the gut. The IPD probe also has an optical fiber inside the channel that enables the acquisition of M-mode OCT images. The M-mode OCT images make it possible to determine when the IPD probe is in contact with the tissue.
One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
Interactive children's medication and wellness tracking system includes a mobile application having a processor, a camera, and a storage device. The storage device is commutatively coupled to the processor, and includes scanning logic to extract medication data from at least one picture or video stream captured by the camera. The system can also include a graphical display logic to receive child data associated with at least one child of a user. Communication logic can transmit the medication data to a children's medication server and subsequently receive dosage data in response to the transmitted medication data. Graphical display logic can further display the proper dosage of the scanned medicine wherein the dosage is based on at least the child data, and dosage data. The proper dosage may be generated within the mobile application or can be generated within the children's medication server and transmitted to the mobile application for display.
BACKGROUND Peritoneal dialysis (PD) serves as a critical renal replacement therapy for individuals with end-stage renal disease (ESRD), leveraging the peritoneum for fluid and substance exchange. Despite its effectiveness, PD is marred by complications such as peritonitis, which significantly impacts patient outcomes. The novelty of our report lies in the presentation of a rare case of PD-associated peritonitis caused by 2 unusual pathogens, emphasizing the importance of rigorous infection control measures. CASE REPORT We report on an 80-year-old African-American female patient with ESRD undergoing PD, who was admitted twice within 8 months for non-recurring episodes of peritonitis. These episodes were attributed to the rare pathogens Achromobacter denitrificans/xylosoxidans and Carbapenem-resistant Acinetobacter baumannii. Despite presenting with similar symptoms during each episode, such as abdominal pain and turbid dialysis effluent, the presence of these uncommon bacteria highlights the intricate challenges in managing infections associated with PD. The treatment strategy encompassed targeted antibiotic therapy, determined through susceptibility testing. Notably, the decision to remove the PD catheter followed extensive patient education, ensuring the patient comprehended the rationale behind this approach. This crucial step, along with the subsequent shift to hemodialysis, was pivotal in resolving the infection, illustrating the importance of patient involvement in the management of complex PD-related infections. CONCLUSIONS This case underscores the complexities of managing PD-associated peritonitis, particularly with uncommon and resistant bacteria. It emphasizes the importance of rigorous infection control measures, the need to consider atypical pathogens, and the critical role of patient involvement in treatment decisions. Our insights advocate for a more informed approach to handling such infections, aiming to reduce morbidity and improve patient outcomes. The examination of the literature on recurrent peritonitis and treatment strategies provides key perspectives for navigating these challenging cases effectively.
Infertility is closely related to obesity. Relative fat mass (RFM) is a newer index for assessing percentage of body fat, which reflects the amount of body fat better than body mass index (BMI), but its relationship with infertility needs further study. The purpose of this study was to assess whether there was an association between RFM and infertility in women aged 20 to 44 years in the United States. The corresponding participants were selected from the National Health and Nutrition Examination Survey (NHANES) 2013 to 2018. RFM was used as the independent variable and infertility as the dependent variable. Multiple logistic regression and generalized additive models were used to explore the association between RFM and infertility, 2-stage linear regression models were used to calculate threshold effects, and subgroup analyses and tests of interactivity were used to find sensitive populations. A total of 2328 women aged 20 to 44 years were included. In the fully adjusted model, the risk of infertility increased by 6% for each increase in RFM (OR = 1.06, 95% CI: 1.00-1.12). There was a nonlinear relationship between RFM and infertility with 2 breakpoints of K1 = 31.04 and K2 = 48.4. There was a positive association between RFM and infertility on the right side of K1 and, on the left side of K2 (OR = 1.08, 95% CI: 1.01-1.16; OR = 1.07, 95% CI: 1.01-1.14). In contrast, no statistically significant association between RFM and infertility was found on the left side of K1 as well as on the right side of K2. There was a nonlinear relationship between RFM and infertility, with a positive association with infertility when RFM was in the range of 31.04 to 48.4.This suggests that RFM may be an alternative to BMI in the management of obese infertile women, but this needs to be further confirmed by prospective studies.
The present invention provides mouse antihuman lipopolysaccharide acceptor antibody heavy chain and light chain variable region gene named as CD14 internationally, and clones antibody named ZCH-7-2F9 and possessing the nucleotide sequences of SEQ ID No. 1 and SEQ ID No. 2 and amino acid sequences of SEQ ID No. 3 and SEQ ID No. 4. The present invention provides the cloning and sequencing of antihuman CD14 antibody (ZCH-7-2F9) heavy chain and light chain variable region gene. The humanized gene engineering antibody developed based on the gene sequence may have important application value in clinical target treatment of acute monocytic leukaemia and may be used in preparing medicine for treating acute monocytic leukaemia.
NEW MATERIAL:A compound shown by the formulaI(R1 is H, Li, Na, K, Ca, CH3, C2H5, phthalidyl, etc.; R2 and R3 are H, lower alkyl, halogen-substituted alkyl; R4-R7 are H, F, Cl, Br, OH, etc.) or its salt. EXAMLE:7-Chloro-6-fluoro-4-hydroxy-2-mercaptoquinoline-3-carboxylic acid ethyl ester. USE:An antibacterial agent or an inexpensive intermediate for preparing a compound shown by the formula II showing activity against Gram-positive and Gram-negative bacteria by its very small amount. PROCESS:A substituted aniline shown by the formula III is made into a compound shown by the formula IV by a well-known method, it is reacted with sodium salt of diethyl malonate to give a compound shown by the formula V, which is protected with a substituted alkyl R2, subjected to ring closure by heating, to give a compound shown by the formulaIwhere R3 is H.
Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
Inflammatory myofibroblastic tumors (IMTs) are one of the most complex and rare neoplasms that have been discovered, with varying behavior in different cases. They mostly arise in the thoracic and abdominal cavity, the lungs, retroperitoneum, and extremities. They can also be detected in the head and neck area. IMTs have no age or gender preference which makes them tougher to anticipate. Head and neck IMTs are benign neoplasms with locally aggressive behavior and a low risk of metastatic spread. They have an unknown etiology, and they resemble malignant lesions radiologically. In this case report, we will review the case of a 40-year-old woman with an unusual IMT in the maxillary sinus that presented as a challenge in diagnosis and management.
Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
We aimed to reveal interrelationships between alexithymia, catastrophic thinking, sensory processing patterns, and dental anxiety among 460 participants who were registrants of a Japanese research company. Measures used were the Modified Dental Anxiety Scale, the Adult Sensory Profile, the Pain Catastrophizing Scale, and the 20-item Toronto Alexithymia Scale. The interrelationships among the constructs were analyzed using structural equation modeling, adjusting for age, gender, and negative dental treatment experience. Data from 428 participants were used in the analyses. Sensory sensitivity and pain catastrophizing were independently associated with anticipatory and treatment-related dental anxiety, while difficulty identifying feelings was not. In the mediation model, sensory sensitivity and pain catastrophizing served as full mediators between difficulty identifying feelings and the dimensions of dental anxiety (indirect effects were between 0.13 and 0.15). The strength of the associations was 0.55 from difficulty identifying feelings to both pain catastrophizing and sensory sensitivity, and between 0.24 and 0.26 to anticipatory and treatment-related dental anxiety. The association between trait-like phenomena, such as alexithymia, and dental anxiety may be mediated by neurophysiological and cognitive factors such as sensory sensitivity and pain catastrophizing. These findings could be crucial for new and innovative interventions for managing dental anxiety.
Bone-anchored percutaneous implants, commonly referred to as osseointegrated implants, are gaining popularity as an alternative to sockets for attaching a prosthetic limb to an amputated femur. While these implants have several advantages, femoral fractures are relatively common in these patients, occurring in 6.3% of femurs within 4 years. This study aimed to develop a novel method to quantify femoral strength under all possible external loads acting on the distal implant. Finite element analysis was used to explore combinations of forces and moments that, when applied on the bone-anchored implant, were just sufficient to fracture the femur. The 6-dimensional envelope generated in the current study provided a quantitative description of the strength of the femur-implant construct. All the femoral fractures were predicted in the trochanteric region, corresponding to where most in vivo fractures have been reported. The 6-dimensional envelopes developed in the current study may be useful in the design of fail-safe devices that could reduce femoral fractures in patients with bone-anchored percutaneous femoral implants. The framework presented may also be used for determining patient suitability for bone-anchored percutaneous implants, and for evaluating the functional performance of implant designs.
BACKGROUND: The atherogenic index of plasma (AIP) is closely associated with the onset of diabetes, with obesity being a significant risk factor for type 2 diabetes mellitus (T2DM). However, the association between the AIP and T2DM in overweight and obese populations has been infrequently studied. Therefore, this study aimed to explore this association in overweight and obese individuals with T2DM.
METHODS: This cross-sectional analysis utilized data from 40,633 participants with a body mass index (BMI) ≥ 24 kg/m2 who were screened from January 2018 to December 2023 at Henan Provincial People's Hospital. Participants were categorized into groups of overweight and obese individuals with and without diabetes according to the T2DM criteria. The AIP, our dependent variable, was calculated using the formula log10 [(TG mol/L)/HDL-C (mol/L)]. We investigated the association between the AIP and T2DM in overweight and obese individuals using multivariate logistic regression, subgroup analysis, generalized additive models, smoothed curve fitting, and threshold effect analysis. Additionally, mediation analysis evaluated the role of inflammatory cells in AIP-related T2DM.
RESULTS: Overweight and obese patients with T2DM exhibited higher AIP levels than those without diabetes. After adjusting for confounders, our results indicated a significant association between the AIP and the risk of T2DM in overweight and obese individuals (odds ratio (OR) = 5.17, 95% confidence interval (CI) 4.69-5.69). Notably, participants with a high baseline AIP (Q4 group) had a significantly greater risk of T2DM than those in the Q1 group, with an OR of 3.18 (95% CI 2.94-3.45). Subgroup analysis revealed that the association between the AIP and T2DM decreased with increasing age (interaction P < 0.001). In overweight and obese populations, the association between AIP and T2DM risk displayed a J-shaped nonlinear pattern, with AIP > - 0.07 indicating a significant increase in T2DM risk. Various inflammatory cells, including neutrophils, leukocytes, and monocytes, mediated 4.66%, 4.16%, and 1.93% of the associations, respectively.
CONCLUSION: In overweight and obese individuals, the AIP was independently associated with T2DM, exhibiting a nonlinear association. Additionally, the association between the AIP and T2DM decreased with advancing age. Multiple types of inflammatory cells mediate this association.
<P>PROBLEM TO BE SOLVED: To provide a water-in-oil type emulsified cosmetic that has a high internal water phase ratio to allow good serviceability and exhibits good emulsion stability though it is a water-in-oil type solid emulsified cosmetic exhibiting good makeup sustainability and having a refreshing feeling to the skin.  <P>SOLUTION: The water-in-oil type emulsified cosmetic contains the following components (A), (B), (C) and (D), and satisfies the requirements (1) and (2) below. Components: (A) one or two or more selected from among glycerin monooleate, glycerine monoisostearate and polyoxyethylene glyceryl monostearate; (B) an aqueous component; (C) an oily component; and (D) a powder. Requirements: (1) The internal water phase ratio which is obtained by dividing the sum of the mass of the component (A) and the component (B), the aqueous component, by the sum of the mass of the component (A), the component (B), the aqueous component, and the component (C), the oily component, is at least 50%. (2) For the component (A), the purity of glycerine monooleate is at least 90 mass% based on the total amount of glycerin monooleate, glycerine dioleate and glycerine trioleate; the purity of glycerine monoisostearate is at least 90 mass% based on the total amount of glycerine monoisostearate, glycerine diisostearate and glycerine triisostearate; and the purity of polyoxyethylene glyceryl monostearate is at least 90 mass% based on the total amount of polyoxyethylene glyceryl monostearate, polyoxyethylene glyceryl distearate and polyoxyethylene glyceryl tristearate.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This study consists of 2 parts. Part 1 is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving), randomized (treatment group assigned by chance), 3-way crossover (a method used to switch participants from one treatment group to another in a clinical trial) study to estimate drug-drug interaction between VX-787 and oseltamivir. It consists of 3 phases: a Screening phase, a Treatment phase and a Follow-up phase. Treatment phase will include 3 treatment sessions, each of the participant will receive Treatment A (VX-787, 600 milligram \[mg\] 2 times a day on Day 1 to 4, followed by a single dose of VX 787, 600 mg on Day 5); Treatment B (Oseltamivir, 75 mg 2 times a day on Day 1 to 4, followed by a single dose of oseltamivir 75 mg on Day 5) and Treatment C (VX-787, 600 mg 2 times a day + oseltamivir, 75 mg 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + a single dose of oseltamivir, 75 mg on Day 5). Each treatment session will be separated by a wash-out period of 5 days. The order each participant will receive treatments A, B and C will be decided at randomization.

Part 2 is double-blind (a medical research study in which neither the researchers nor the participants know what treatment the subjects is receiving), randomized, placebo-controlled. It consists of 3 phases: a Screening phase, a Treatment phase and a Follow-up phase. In Treatment phase participants will be randomly assigned VX-787, 600 mg or placebo 2 times a day, on Day 1 to 9, followed by a single dose of VX-787 600 mg or placebo in the morning on Day 10. Pharmacokinetic parameters will be assessed primarily. Participants' safety will be monitored throughout the study.
Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
PaRIS-IOR is a prospective observational study that aims to collect and analyze functional outcomes and quality of life reported by patients undergoing elective hip, knee and shoulder arthroplasty at the IRCCS Rizzoli Orthopedic Institute (IOR). IOR was selected as a pilot center for the launch of the OECD's PaRIS Initiative in Italy, whose purpose is to accelerate the adoption and reporting of validated, standardised, internationally-comparable patient-reported indicators, particularly within patient registries.

PaRIS-IOR's study population will consist of consecutive patients undergoing hip, knee and shoulder arthroplasty performed at 6 Operative Units of the IOR. The study will last 30 months and will include a 12-month recruitment period, a 12-month follow-up and 6 months for data analysis and reporting. Functional outcomes and quality of life will be detected through the administration of validated questionnaires (EQ-5D, HOOS, KOOS, ASES). The questionnaires will be administered in the month preceding the surgical procedure in the clinic or in the ward, while the 2 follow-up questionnaires will be send by mail at patients' home. The collected data will be combined with those routinely collected by the Registry of Orthopedic Prosthetic Implantology (RIPO), already active at the IOR since year 1990.